<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ETHOSUXIMIDE <img border="0" src="../images/pr.gif"/></span><br/>(eth-oh-sux'i-mide)<br/><span class="topboxtradename">Zarontin<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">succinimide anticonvulsant</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg capsules; 250 mg/5 mL syrup</p>
<h1><a name="action">Actions</a></h1>
<p>Succinimide anticonvulsant. Usually ineffective in management of psychomotor or major motor seizures.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Reduces frequency of epileptiform attacks, apparently by depressing motor cortex and elevating CNS threshold to stimuli.</p>
<h1><a name="uses">Uses</a></h1>
<p>Management of absence (petit mal) seizures, myoclonic seizures, and akinetic epilepsy. May be administered with other anticonvulsants
         when other forms of epilepsy coexist with petit mal.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to succinimides; severe liver or kidney disease; use alone in mixed types of epilepsy (may increase frequency
         of grand mal seizures). Safety during pregnancy (category C), lactation, or in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Absence Seizures</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">PO</span> <i>612 y</i>, 250 mg b.i.d., may increase q47d prn (max: 1.5 g/d)<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> <i>36 y</i>, 250 mg/d, may increase q47d prn (max: 1.5 g/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food if GI distress occurs.</li>
<li>Store all forms at 15°30° C (59°86° F); capsules in tight containers, and syrup in light-resistant
            containers; avoid freezing.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Drowsiness, hiccups, ataxia, dizziness, headache, euphoria, restlessness, irritability, anxiety, hyperactivity, aggressiveness,
      inability to concentrate, lethargy, confusion, sleep disturbances, night terrors, hypochondriacal behavior, muscle weakness,
      fatigue. <span class="typehead">Special Senses:</span> Myopia. <span class="typehead">GI:</span> Nausea, vomiting, <span class="speceff-common">anorexia, epigastric distress,</span> abdominal pain, <span class="speceff-common">weight loss,</span> diarrhea, constipation, gingival hyperplasia. <span class="typehead">Urogenital:</span> Vaginal bleeding. <span class="typehead">Hematologic:</span> Eosinophilia, leukopenia, thrombocytopenia, <span class="speceff-life">agranulocytosis, pancytopenia, aplastic anemia</span>, positive direct Coombs' test. <span class="typehead">Skin:</span> Hirsutism, pruritic erythematous skin eruptions, urticaria, alopecia, erythema multiforme, exfoliative dermatitis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Carbamazepine</b> decreases ethosuximide levels; <b>isoniazid</b> significantly increases ethosuximide levels; levels of both <b>phenobarbital</b> and ethosuximide may be altered with increased seizure frequency. <span class="typehead">Herbal:</span> <b>Ginkgo</b> may decrease anticonvulsant effectiveness. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 4 h; steady state: 47 d. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted slowly in urine; small amounts excreted in bile and feces. <span class="typehead">Half-Life:</span> 30 h in children, 60 h in adults. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Perform baseline and periodic hematologic studies, liver and kidney function.</li>
<li>Monitor adverse drug effects. GI symptoms, drowsiness, ataxia, dizziness, and other neurologic adverse effects occur frequently
            and indicate the need for dosage adjustment.
         </li>
<li>Observe closely during period of dosage adjustment and whenever other medications are added or eliminated from the drug regimen.
            Therapeutic serum levels: 4080 mcg/mL.
         </li>
<li>Observe patients with prior history of psychiatric disturbances for behavioral changes. Close supervision is indicated. Drug
            should be withdrawn slowly if these symptoms appear.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Discontinue drug only under physician supervision; abrupt withdrawal of ethosuximide (whether used alone or in combination
            therapy) may precipitate seizures or petit mal status.
         </li>
<li>Do not drive or engage in other potentially hazardous activities until response to drug is known.</li>
<li>Monitor weight on a weekly basis. Report anorexia and weight loss to physician; may indicate need to reduce dosage.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>